827 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Downtrend
Article Searches
Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You https://www.fool.com/investing/2019/02/27/big-pharmas-showdown-with-congress-over-drug-prici.aspx?source=iedfolrf0000001 Feb 27, 2019 - A Senate committee roasted top executives of the biggest drugmakers. But will anything change for ordinary Americans?
Congress Grills Drugmakers: 5 Key Takeaways https://www.fool.com/investing/2019/02/26/congress-grills-drugmakers-5-key-takeaways.aspx?source=iedfolrf0000001 Feb 26, 2019 - Top drug companies addressed sky-high drug prices on Capitol Hill today.
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $7.7 million of Shares http://www.gurufocus.com/news/821392/merck--co-inc-mrk-chairman-president--ceo-kenneth-c-frazier-sold-77-million-of-shares Feb 22, 2019 - Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $7.7 million of Shares, Stocks: MRK, release date:Feb 22, 2019
Merck to Buy Immunotherapy Developer Immune Design for $300M http://www.zacks.com/stock/news/356654/merck-to-buy-immunotherapy-developer-immune-design-for-%24300m?cid=CS-ZC-FT-356654 Feb 22, 2019 - Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.
What's in the Cards for Perrigo (PRGO) This Earnings Season? http://www.zacks.com/stock/news/356476/whats-in-the-cards-for-perrigo-prgo-this-earnings-season?cid=CS-ZC-FT-356476 Feb 22, 2019 - Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-ZC-FT-356445 Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review http://www.zacks.com/stock/news/356394/dow-30-stock-roundup-wmt-earnings-beat-mrks-keytruda-sbla-gets-priority-review?cid=CS-ZC-FT-356394 Feb 22, 2019 - The index endured a holiday-shortened but volatile week.
Merck Gets Priority Review for Keytruda in Third-Line SCLC http://www.zacks.com/stock/news/355982/merck-gets-priority-review-for-keytruda-in-third-line-sclc?cid=CS-ZC-FT-355982 Feb 21, 2019 - Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio http://www.zacks.com/stock/news/355599/why-merck-mrk-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-355599 Feb 20, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study http://www.zacks.com/stock/news/355533/mercks-keytruda-fails-to-meet-endpoint-in-liver-cancer-study?cid=CS-ZC-FT-355533 Feb 20, 2019 - Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.

Pages: 123456789101112...83

<<<Page 7>